NEW YORK, April 30, 2012 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Gen-Probe, Inc. ("Gen-Probe" or the "Company") (NASDAQ: GPRO) concerning the proposed acquisition of the Company by Hologic, Inc. ("Hologic") in a transaction valued at approximately $3.7 billion.
On April 30, 2012, it was announced that Gen-Probe and Hologic have entered into a definitive agreement pursuant to which Hologic will acquire Gen-Probe. Under the agreement, Gen-Probe shareholders will receive $82.75 per share.
Our investigation concerns whether the Gen-Probe board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company shareholders.
If you own Gen-Probe shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Benjamin Sachs-Michaels Robert I. Harwood, Esq. Harwood Feffer LLP 488 Madison Avenue New York, New York 10022 Phone Numbers: (877) 935-7400 (212) 935-7400 Email: [email protected] Website: http://www.hfesq.com
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.